Releases
PRPO
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest PRECIPIO (PRPO) stock and general news. This information may help you make smarter investment decisions.
About PRPO
Precipio, Inc. is a cancer diagnostics and reagent technology company providing diagnostic products and services to the oncology market. The Company is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture based tests by a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. The Company operate a cancer diagnostic laboratory located in New Haven.